Site Variability in Cerebral Embolic Protection for Transcatheter Aortic Valve Implantation and Association With Outcomes

Ubaid, Aamer; Kennedy, Kevin F.; Chhatriwalla, Adnan K.; Saxon, John; Hart, Anthony; Allen, Keith B.; Aberle, Corinne; Shatla, Islam; Abumoawad, Abdelrhman; Gunta, Satya Preetham; Skolnick, David G.; Huded, Chetan

doi:10.1016/j.shj.2023.100202

Structural Heart

2023

DOI: 10.1016/j.shj.2023.100202

|View full text |Cite

Site Variability in Cerebral Embolic Protection for Transcatheter Aortic Valve Implantation and Association With Outcomes

Aamer Ubaid

Kevin F. Kennedy

Adnan K. Chhatriwalla

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical impact of cerebral protection during transcatheter aortic valve implantation

Boccuto,

Carabetta,

Cacia

et al. 2024

Eur J Clin Investigation

View full text Add to dashboard Cite

BackgroundEmbolization of debris can complicate transcatheter aortic valve implantation (TAVI) causing stroke. Cerebral embolism protection (CEP) devices can divert or trap debris.PurposeTo evaluate the efficacy of CEP during TAVI vs the standard procedure.Data SourcesPubMed, SCOPUS and DOAJ 1/01/2014–04/12/2023.Study SelectionRandomized and observational studies comparing CEP versus standard TAVI, according to PRISMA. Primary outcome: stroke. Secondary outcomes: death, bleeding, vascular access complications, acute kidney injury and infarct area.Data ExtractionTwo investigators independently assessed study quality and extracted data.Data SynthesisTwenty‐six articles were included (540.247 patients). The primary endpoint was significantly lower (RR = 0.800 95%CI:0.682–0.940; p = 0.007) with CEP. Similarly, death rates were significantly lower with CEP (RR = 0.610 95%CI:0.482–0.771; p < 0.001). No difference was found for bleeding (RR = 1.053 95%CI:0.793–1.398; p = 0.721), vascular complications (RR = 0.937 95%CI:0.820–1.070; p = 0.334) or AKI (RR = 0.982 95%CI:0.754–1.279; p = 0.891).ConclusionsUse of CEP during TAVI is associated with improved outcomes. Future studies will identify patients who benefit most from CEP.

show abstract

Clinical impact of cerebral protection during transcatheter aortic valve implantation

Boccuto,

Carabetta,

Cacia

et al. 2024

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Site Variability in Cerebral Embolic Protection for Transcatheter Aortic Valve Implantation and Association With Outcomes

Cited by 1 publication

References 18 publications

Clinical impact of cerebral protection during transcatheter aortic valve implantation

Clinical impact of cerebral protection during transcatheter aortic valve implantation

Contact Info

Product

Resources

About